Cytoreductive surgery and adjuvant immunotherapy in the management of metastatic melanoma

Tumori

Volumn 87, Issue 4, 2001, Pages

  Morton, D L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; MELANOMA VACCINE;

CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; MELANOMA; METASTASIS; SURGICAL TECHNIQUE; SURVIVAL TIME;

EID: 0034804524     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160108700433     Document Type: Conference Paper

References (11)

1. Cytoreductive surgery and adjuvant immunotherapy: A new management paradigm for metastatic melanoma
2. Prognostic factors in 1,521 melanoma patients with distant metastases
3. Surgical resection as the treatment of choice for melanoma metastatic to the lung
4. Surgical resection for melanoma metastatic to the gastrointestinal tract
5. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax
6. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
7. Active immunotherapy with allogeneic tumor cell vaccines: Present status
8. Cytoreductive surgery and adjuvant postoperative immunotherapy with polyvalent melanoma vaccine enhances survival for stage IV melanoma: Results of matched-pair analysis
9. Vaccine therapy for malignant melanoma
10. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model
11. Correlation of specific immune responses with survival in patients receiving polyvalent melanoma cell vaccine